Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Tuesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Up 1.0 %

Shares of NYSE:ENZ opened at $0.71 on Tuesday. The company has a 50 day moving average of $1.07 and a 200 day moving average of $1.10. Enzo Biochem has a 12 month low of $0.68 and a 12 month high of $1.50.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were issued a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a yield of 56.14%. The ex-dividend date of this dividend was Friday, November 15th.

Hedge Funds Weigh In On Enzo Biochem

Large investors have recently bought and sold shares of the stock. BBR Partners LLC bought a new position in shares of Enzo Biochem in the third quarter worth approximately $112,000. Renaissance Technologies LLC boosted its position in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the period. XTX Topco Ltd grew its holdings in Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the period. 36.90% of the stock is owned by hedge funds and other institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.